Clinical Trial Update: Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del [Phase 3]

View source ↗

Summary

Phase 3 safety and pharmacokinetic study of lumacaftor/ivacaftor in children aged 1 to under 2 years with cystic fibrosis (homozygous F508del) is completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2023-01-06